These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24217803)

  • 41. Effects of Conversion From Calcineurin Inhibitors to Sirolimus or Everolimus on Renal Function and Possible Mechanisms in Liver Transplant Recipients.
    Tsai KF; Li LC; Hsu CN; Lin CC; Lin YH; Cheng YF; Wang CC; Chen CL
    J Clin Pharmacol; 2019 Mar; 59(3):326-334. PubMed ID: 30387865
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sirolimus and everolimus in kidney transplantation.
    Moes DJ; Guchelaar HJ; de Fijter JW
    Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapamycin Inhibitors for Eye Squamous Cell Carcinoma after Renal Transplantation: A Case Report.
    Infante B; Coviello N; Troise D; Gravina M; Bux V; Castellano G; Stallone G
    Kidney Blood Press Res; 2021; 46(1):121-125. PubMed ID: 33508825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M; Van Der Giet M
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
    Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of mineral and bone disorder after kidney transplantation.
    Kalantar-Zadeh K; Molnar MZ; Kovesdy CP; Mucsi I; Bunnapradist S
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):389-403. PubMed ID: 22614626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report.
    Pascual J; Fernández AM; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii38-41. PubMed ID: 16815857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review.
    Ponticelli C; Scolari MP
    Transplant Proc; 2010; 42(6):2205-8. PubMed ID: 20692445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
    Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
    Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice.
    Cucchiari D; Ríos J; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Rovira J; Torres F; Solè M; Campistol JM; Diekmann F; Oppenheimer F
    J Nephrol; 2020 Jun; 33(3):601-610. PubMed ID: 31853792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
    Kumar J; Bridson JM; Sharma A; Halawa A
    Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunosuppression and Post-transplant Hyperglycemia.
    Montero N; Pascual J
    Curr Diabetes Rev; 2015; 11(3):144-54. PubMed ID: 25824238
    [TBL] [Abstract][Full Text] [Related]  

  • 60. mTOR inhibitors in pediatric kidney transplantation.
    Pape L; Ahlenstiel T
    Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.